PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Mystery explained: How a common chemo drug thwarts graft rejection in bone marrow transplants

2013-11-14
(Press-News.org) Contact information: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine
Mystery explained: How a common chemo drug thwarts graft rejection in bone marrow transplants Results of a Johns Hopkins study may explain why a chemotherapy drug called cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of GVHD.

The findings, published online Nov. 13 in Science Translational Medicine, could pave the way for improvements in preventing GVHD and rejection of transplanted bone marrow and new therapies to prevent or treat a relapse of the underlying cancer after a transplant.

"Finding the optimal conditions to avoid interfering with immune cells working to eradicate cancer while preventing graft rejection and GVHD is the holy grail of bone marrow transplant," says Leo Luznik, M.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center. "We've known for some time that giving cyclophosphamide after a transplant helps prevent GVHD, and our study provides an important piece of the puzzle for why it works."

GVHD occurs when newly transplanted immune cells from a donor's bone marrow attack the patient's body. Commonly used immunosuppressant drugs prevent rapid-onset, acute GVHD but not persistent, long-lasting, chronic GVHD, which may cause severe disability and death.

In the early 2000s, Johns Hopkins scientists Leo Luznik and Ephraim Fuchs found that giving patients high doses of cyclophosphamide – a drug derived from nitrogen mustard and used to treat blood cancers – three days after bone marrow transplant successfully thwarts acute and chronic GVHD. Johns Hopkins physicians also found that post-transplant cyclophosphamide enabled safe administration of new, half-matched bone marrow transplants in addition to traditional, fully matched ones. Medical centers around the world now use the Johns Hopkins protocol of post-transplant cyclophosphamide, and Luznik says the inexpensive drug is becoming increasingly mainstream in bone marrow transplant regimens.

Some of the first clues to how cyclophosphamide works were also discovered in the 1980s by Johns Hopkins scientists. They found that cyclophosphamide kills all of the donor's transplanted bone marrow cells except for stem cells containing high levels of an enzyme called aldehyde dehydrogenase (ALDH). The ALDH-laden stem cells evade the toxic effects of cyclophosphamide and rebuild the patient's immune system. Richard Jones, M.D., professor and director of the Bone Marrow Transplant Program at Johns Hopkins, developed a now commonly used assay to study ALDH levels in individual cells.

Yet, scientists lacked an explanation for why post-transplant cyclophosphamide effectively curtailed acute and chronic GVHD.

Luznik and his team inventoried types of immune cells present in the blood of bone marrow transplant patients treated with post-transplant cyclophosphamide. The scientists zeroed in on a type of immune cell called regulatory T-cells, which were known to suppress autoimmune responses. They found high levels of the regulatory T-cells in patients treated with post-transplant cyclophosphamide, and lab-cultured cells survived cyclophosphamide treatment. Using polymerase chain reaction methods that amplify DNA and Jones' assay that detects by-products of ALDH, the Johns Hopkins team found that regulatory T-cells express high levels of ALDH.

"These regulatory T-cells are resistant to post-transplant cyclophosphamide and likely subdue the autoimmune-like response of the donor's bone marrow, preventing GVHD," says Christopher Kanakry, M.D., first author of the study and clinical fellow at the Johns Hopkins Kimmel Cancer Center. Patients receiving standard immunosuppressive drugs after transplant, as opposed to high-dose cyclophosphamide, have slower recovery of regulatory T-cells in their blood, adds Kanakry.

The scientists also showed, in lab-cultured human cells, that an ALDH-blocking drug strips regulatory T-cells of their ability to grow and protect themselves from cyclophosphamide.

Luznik says his team is continuing to study methods to improve post-transplant cyclophosphamide, and it may be possible to use these findings to add other relapse-fighting therapies early after transplant. "Our findings may also lead to even wider acceptance of post-transplant cyclophosphamide," he said.

Funding for the study was provided by the National Institutes of Health, National Cancer Institute and National Heart, Lung, and Blood Institute (HL110907, CA122779, CA15396, UL1-RRO25005, and HL007525), the Conquer Cancer Foundation of the American Society of Clinical Oncology and Otsuka Pharmaceutical.

The assay (Aldefluor) used in this research was developed and patented by Richard Jones. Under a licensing agreement between Aldagen and the Johns Hopkins University, Jones is entitled to a share of royalties received by the University. The terms of this arrangement are managed by Johns Hopkins University in accordance with its conflict-of-interest policies.

### In addition to Luznik, Kanakry and Jones, scientists contributing to the research include Sudipto Ganguly, Marianna Zahurak, Javier Bolaños-Meade, Christopher Thoburn, Brandy Perkins, Ephraim Fuchs and Allan Hess.

On the Web: Hopkinscancer.org

Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $6.7 billion integrated global health enterprise and one of the leading health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM's vision, "Together, we will deliver the promise of medicine," is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and more than 30 primary health care outpatient sites. The Johns Hopkins Hospital, opened in 1889, was ranked number one in the nation for 21 years in a row by U.S. News & World Report.

Media Contacts: Vanessa Wasta, 410-614-2916
wasta@jhmi.edu Amy Mone, 410-614-2915
amone@jhmi.edu END


ELSE PRESS RELEASES FROM THIS DATE:

Early uses of chili peppers in Mexico

2013-11-14
Early uses of chili peppers in Mexico Mixe-Zoquean cultures may have had multiple culinary uses for chili peppers Chili peppers may have been used to make spicy beverages thousands of years ago in Mexico, according to new research published November 13 in the ...

Scorpions use strongest defense mechanisms when under attack

2013-11-14
Scorpions use strongest defense mechanisms when under attack Scorpions tend to use their strongest defense mechanisms, according to new research published November 13 in the open-access journal PLOS ONE by Arie van der Meijden and colleagues at Centro de Investigação ...

The 'evolution' of Little Red Riding Hood

2013-11-14
The 'evolution' of Little Red Riding Hood New analysis reveals whether different folktales are related or not Evolutionary analysis can be used to study similarities among folktales, according to new research published November 13 in the open-access journal PLOS ...

Plasma experiment demonstrates admirable self-control

2013-11-14
Plasma experiment demonstrates admirable self-control Researchers exploit plasma self-organization as a path to economical fusion power A team of Chinese and American scientists has learned how to maintain high fusion performance under steady conditions by exploiting ...

Intranasal insulin improves cognitive function in patients with type 2 diabetes

2013-11-14
Intranasal insulin improves cognitive function in patients with type 2 diabetes BOSTON – In recent years, the link between type 2 diabetes and dementia has become widely recognized. Older individuals with diabetes develop Alzheimer's disease ...

Fantastic phonons: Blocking sound, channeling heat with 'unprecedented precision'

2013-11-14
Fantastic phonons: Blocking sound, channeling heat with 'unprecedented precision' Imagine living on a bustling city block, but free from the noise of car horns and people on the street. The emerging field of phononics could one day make this ...

Feral cats avoid urban coyotes, are surprisingly healthy

2013-11-14
Feral cats avoid urban coyotes, are surprisingly healthy Study suggests urban coyotes may 'protect' certain wildlife from cats COLUMBUS, Ohio -- Cats that live outdoors in the city do their darnedest to steer clear of urban coyotes, a new study says. The cats cause less ...

NASA sees a re-awakening of ex-Depression 30W in a different ocean

2013-11-14
NASA sees a re-awakening of ex-Depression 30W in a different ocean The former tropical storm known as 30W that moved from the western North Pacific Ocean basin into the northern Indian Ocean appears to be ramping up for a short stint at depression status again. ...

Lifting fusion power onto an (optimized) pedestal

2013-11-14
Lifting fusion power onto an (optimized) pedestal New insights into a fusion plasma's transport barrier promise to boost future reactor performance In a collaborative effort, researchers in the United States and the United Kingdom have developed a new technique that ...

New antenna spreads good vibrations in fusion plasma

2013-11-14
New antenna spreads good vibrations in fusion plasma 'Shoelace Antenna' exploits naturally occurring resonant vibrations to regulate heat and particle flow through the plasma boundary in a tokamak fusion reactor If you want to catch a firefly, any old glass jar will ...

LAST 30 PRESS RELEASES:

Storing breast milk for specific times of day could support babies’ circadian rhythm

Growing a new, pencil-shaped structure of gold named “quantum needles”

Transparent mesoporous WO₃ film enhances solar water splitting efficiency and stability

Protostellar jet detection in Milky Way’s outer region reveals universal star formation

New research uncovers a ‘ghost’ of the Australian bush

Study establishes link between rugby and dementia

Can courts safeguard fairness in an AI age?

Less than half of England has access to Mounjaro on the NHS months after roll-out

Study highlights cultural differences in parenting and reveals that how babies are soothed matters more than how fast

Claims on baby food fail to stack up

Potential molecular link between air pollutants and increased risk of Lewy body dementia revealed

Deaths from high blood pressure-related kidney disease up nearly 50% in the past 25 years

U.S. survey finds salt substitutes rarely used by people with high blood pressure

Researchers map key human proteins that power coronavirus replication, pointing to new treatment strategies

Single hair strand could provide biomarker for ALS, Mount Sinai study finds

Bio-oil made with corn stalks, wood debris could plug orphaned fossil fuel wells

Can the 'good' bacteria in your mouth act as probiotic cavity fighters?

This common fish has an uncommon feature: Forehead teeth, used for mating

UI Health performs first islet cell transplant with Lantidra

Study shows not all dietary proteins are digested the same way

MSU study finds accessible wireless ultrasounds are accurate

Scientists review breakthrough methods to disrupt toxic “forever chemicals” in water

Ghost sharks grow forehead teeth to help them have sex

How stress and social struggles fuel America’s obesity crisis

Researchers uncover similarities between human and AI learning

Researchers achieve light-induced heterolytic hydrogen dissociation at ambient temperature

Intestinal surface cells pull rather than push

Game-changing biotech for engineering pathogen-resistant crops

Evolution of rodents’ unique thumbnail contributed to their successful radiation

Estrogen-driven cell regeneration shields female kidneys from disease

[Press-News.org] Mystery explained: How a common chemo drug thwarts graft rejection in bone marrow transplants